Durable improvement in clinical outcomes with alemtuzumab following switch from subcutaneous interferon beta-1a in treatment-naive patients with active RRMS: three-year follow-up of the CARE-MS I extension study

被引:0
作者
Hartung, H. -P. [1 ]
Arnold, D. L. [2 ,3 ]
Cohen, J. A. [4 ]
Coles, A. J. [5 ]
Fox, E. J. [6 ]
Havrdova, E. [7 ]
Selmaj, K. W. [8 ]
Margolin, D. H.
Kasten, L. [10 ]
Panzara, M. A. [9 ]
Compston, D. A. S. [5 ]
机构
[1] Univ Dusseldorf, Dusseldorf, Germany
[2] NeuroRx Res, Montreal, PQ, Canada
[3] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Univ Cambridge, Sch Clin Med, Cambridge, England
[6] Cent Texas Neurol Consultants, Round Rock, TX USA
[7] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[8] Med Univ Lodz, Lodz, Poland
[9] Genzyme, Cambridge, MA USA
[10] PROMETRIKA LLC, Cambridge, MA USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P1096
引用
收藏
页码:565 / 566
页数:2
相关论文
empty
未找到相关数据